Alpha memo: cancer selenium vitamin prevention endpoint split

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Reconcile the title's 'endpoint split' framing with what Receipt 1 actually shows. Receipt 1 is a baseline-biomarker case-cohort analysis with a selenium-interaction subgroup finding, NOT a supplementation-arm confirmation of the original SELECT prostate excess. The memo should either narrow its claim (e.g., 'SELECT secondary analyses converge on null-to-adverse, with a baseline plasma α-tocopherol × selenomethionine interaction as the most actionable signal') or add a third receipt covering the vitamin E randomization arm's prostate cancer result (Lippman 2009, JAMA) to anchor the supplementation-vs-baseline distinction.
2. Explicitly report Receipt 1's key statistics in the body: overall Q5 vs Q1 HR 1.21 (0.88–1.66, P-trend 0.24); placebo-arm Q5 HR 0.85; selenomethionine-arm Q5 HR 2.04 (1.29–3.22); high-grade overall Q5 HR 1.59 (1.13–2.24). These are essential to the reader's interpretation and were underrepresented.
3. Soften 'endpoint-gated' causal language to 'endpoint-heterogeneous' or 'tissue-heterogeneous' and explicitly state this is a tentative cross-context contrast across two non-randomized-against-each-other secondary analyses, not a within-trial endpoint comparison.
4. Add a falsifier for the selenium-interaction subgroup in Receipt 1 (e.g., an independent cohort failing to replicate the α-tocopherol × selenomethionine interaction on high-grade disease).

Major issues

• Title promises a 'cancer selenium vitamin prevention endpoint split' framing, but the central analytic novelty claim — that the α-tocopherol excess is endpoint-gated rather than uniformly adverse — is built on Receipt 1 reporting baseline plasma α-tocopherol associations and a selenium interaction, not directly on supplementation-induced prostate vs. bladder contrast. Receipt 2 (bladder null) does not logically demonstrate that α-tocopherol's adverse prostate signal is endpoint-specific; the prostate excess came from the parent trial (vitamin E arm), Receipt 1 examines baseline plasma tocopherols, and Receipt 2 is a sibling null on a different endpoint in different tissue. The 'endpoint-gated' causal language overreaches what two non-comparable secondary analyses can jointly demonstrate.
• Receipt 1 excerpt states baseline plasma α-tocopherol was NOT associated with prostate cancer overall (Q5 vs Q1 HR 1.21, CI 0.88-1.66, P-trend 0.24), and the Q5 vs Q1 in placebo arm HR was 0.85 — yet the memo's Receipt 1 description claims 'higher presupplementation α-tocopherol concentrations showed risk similar to those with lower concentrations' (consistent) but then frames this as supporting an 'α-tocopherol-driven excess' signal. The receipt's headline is actually a selenium-interaction subgroup finding (Q5 with selenomethionine HR 2.04; high-grade Q5 HR 1.59), which the memo softens. The memo should distinguish baseline plasma biomarker analyses from randomization-arm results and not collapse them into a single 'α-tocopherol excess' claim.

Minor issues

• Receipt 1 description omits the strong selenium-interaction finding (Q5 with selenomethionine HR 2.04) which is arguably the most actionable signal in that paper.
• The 2012 vs 2014 dating note is helpful but the framing 'published two years before the prostate-tocopherol analysis' is correct; however calling Receipt 2 'a clinical update on a different endpoint rather than a direct replication' is underspecified — clarify these are sibling SELECT secondary analyses on different cancer endpoints.
• Sample sizes: Receipt 1 states 1,746 cases from 35,533; Receipt 2 states 34,887 randomized. The 35,533 vs 34,887 difference is minor and unexplained in the memo; flag the discrepancy or note it reflects different analytic denominators.
• Caveats correctly note 53–60 cases per arm in Receipt 2; consider adding the corresponding statistical power implication (≈80% power to detect HR ≤0.6 only, so a modest protective effect cannot be excluded).
• Title uses lowercase 'cancer selenium vitamin prevention endpoint split' which is ungrammatical; consider 'cancer selenium vitamin E prevention: SELECT endpoint split'.

Reviewer note

Bounded alpha-memo pairing two SELECT secondary analyses (bladder null 2012, plasma-tocopherol case-cohort 2014). The bundle exists and abstracts verify the cited statistics. The research question is clear and the limitations/falsifiers section is unusually thorough for an alpha-memo. However, two issues block acceptance. First, the memo's central synthesis — that supplementation's effect is 'endpoint-gated' — overreaches because Receipt 1 is a baseline biomarker analysis (not a supplementation-arm test) with its most striking signal being a selenium-interaction subgroup, and Receipt 2 is a sibling null on a different cancer endpoint in different tissue. Pairing them does not establish endpoint-specificity of the α-tocopherol excess. Second, Receipt 1's headline statistics (overall null, placebo-arm null, strong selenomethionine-interaction HR 2.04, high-grade HR 1.59) are materially underreported while the prose leans on the more equivocal 'risk similar' framing. These are bounded fixes — reframe the central claim as 'endpoint-heterogeneous sibling-secondary signals' and surface Receipt 1's subgroup interaction — making revise the correct triage.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis